Something genuinely good is happening in medicine, and it is easy to miss because of the noise surrounding it.
For most of modern medical history, preventive care meant a once-a-year physical, a cholesterol panel, and advice to eat better and exercise more. The encounter was brief, the recommendations were generic, and the underlying logic was reactive: we would address problems when they became problems. Longevity medicine, at its best, is a rejection of that model. It asks a different question: not what is wrong right now, but what is most likely to limit your health and function over the next twenty or thirty years, and what can we do about it today?
That reorientation is a genuine advance. People are engaging with their health earlier, with more curiosity and more investment, than any previous generation. The movement has brought serious science to the mainstream: research on cellular aging, metabolic health, cardiovascular risk, and cognitive decline that used to live in academic journals is now part of how thoughtful people think about their bodies. That is unambiguously good.
But movements attract opportunists, and the longevity space is no exception. Alongside the science sits an expanding ecosystem of supplements without human evidence, therapies borrowed from research animals, diagnostic tests that generate data without informing decisions, and influencers whose primary credential is a large following. The financial incentives are substantial, the regulatory oversight is thin, and the promises are exactly the kind people want to hear.
I practice longevity medicine. I also hesitate, sometimes, when I use that phrase, because of what it might signal to someone who has encountered the fringe end of this industry. The hesitation is worth examining, because it points directly to what the article is really about: the fundamentals of longevity medicine are not fringe. They are not faddish. They are some of the most robust findings in all of clinical science. The question is how to tell them apart from what is.
What the Evidence Actually Supports
The interventions with the strongest and most consistent evidence for extending healthy lifespan are, at their core, unglamorous. Aerobic exercise and resistance training, performed consistently over years and decades, reduce mortality risk, preserve muscle mass and bone density, protect cognitive function, and improve virtually every measurable marker of metabolic and cardiovascular health. Sleep, consistently seven to nine hours, regulates hormones, clears metabolic waste from the brain, consolidates memory, and is associated with reduced risk of cardiovascular disease, metabolic dysfunction, and dementia. Metabolic health, specifically avoiding chronic insulin resistance and excess visceral fat, is one of the most powerful predictors of long-term health outcomes we have. Managing cardiovascular risk factors aggressively and early, including not just LDL cholesterol but apolipoprotein B, Lp(a), blood pressure, and inflammatory markers, prevents the disease that kills more people than anything else.
None of these require a premium product. None of them came from a conference in Zurich or a podcast interview with a biohacker. They emerged from decades of population research, randomized controlled trials, and clinical observation. They are boring in the best possible way.
Advanced diagnostics can meaningfully extend what we can do with this evidence base. A coronary artery calcium score or coronary CT angiography can identify cardiovascular risk that standard lipid panels miss, changing treatment decisions in patients who would otherwise be told they are fine. A DEXA scan does more than measure bone density: it gives a precise accounting of muscle mass and distribution that a scale and a BMI calculation cannot approximate. Continuous glucose monitoring used outside a diabetic population reveals patterns of postprandial glucose response that predict metabolic disease years before a fasting glucose or HbA1c becomes abnormal. These tools are valuable because they inform clinical decisions. That is the standard they should be held to.
What the Fringe Looks Like
The distinguishing feature of fringe longevity interventions is not that they are necessarily dangerous. Some may eventually prove useful. The distinguishing feature is that they are being offered to patients, often at significant expense, in the absence of meaningful human evidence that they do what they claim.
NAD+ precursor supplementation, for example, is theoretically interesting: NAD+ declines with age, and NAD+ plays a role in cellular energy metabolism and DNA repair. But the gap between "interesting in animal models" and "proven to extend healthy lifespan in humans" is enormous, and most of the commercial enthusiasm around NAD+ IV infusions has outrun what the evidence supports. Exosome therapies, certain peptide protocols, and a range of stem cell offerings occupy similar territory: early-stage research, plausible mechanisms, and commercial availability that has dramatically outpaced clinical validation.
This is a meaningful distinction. In medicine, we have learned, repeatedly, that biological plausibility is not the same as clinical efficacy. The history of promising interventions that failed in controlled trials is long. The responsible approach is not to dismiss emerging science, but to be honest about where on the evidence spectrum a given intervention sits, and to price the uncertainty accordingly.
There is also a subtler category worth naming: diagnostics and interventions that are technically valid but clinically unhelpful. A test that generates a result without changing what you do is not advancing your health. It is generating anxiety, or false reassurance, or both. Part of practicing evidence-based longevity medicine is helping patients understand not just what a test measures, but what you would actually do differently based on the result.
A Framework for Evaluating Claims
When a patient asks me about a longevity intervention, whether it is something they read about or something being offered to them by another provider, I think through a short set of questions.
Is there human evidence, and does it establish clinical outcomes or only biomarker changes? A supplement that raises a circulating marker of interest is not the same as a supplement that reduces disease or mortality. Biomarkers are proxies. What matters is what happens downstream.
Does the recommendation change with the individual, or is it the same advice given to everyone? Genuine personalized medicine is expensive and time-consuming precisely because it requires understanding the specific person. One-size-fits-all protocols dressed up in personalization language are a common feature of the fringe.
Who is selling it, and what do they sell? A physician who recommends a protocol and then provides it for a fee faces a conflict of interest that should be named and examined. This does not automatically make the recommendation wrong, but it should be weighed.
Would a disinterested expert, with no financial stake in the outcome, give the same advice? This is not a perfect filter, but it is a useful one.
The Reason This Matters
There is a real cost when the fringes of the longevity industry crowd out the core. Patients who spend significant resources on unproven interventions are sometimes doing so instead of investing in the things with the strongest evidence. Patients who associate longevity medicine with extreme protocols or biohacker culture may dismiss the entire field, including the parts that could genuinely help them. And physicians who practice this kind of medicine carefully and conservatively have to work harder to establish that their approach is grounded in science, not in the same enthusiasm that drives the supplement industry.
The movement is worth preserving. The question it asks, what can we do now to protect decades of future health, is exactly the right question. The answer, at its foundation, is less novel than the industry sometimes suggests. It involves consistent exercise, restorative sleep, metabolic and cardiovascular risk management taken seriously early, and diagnostic tools used because they inform decisions, not because they signal engagement.
The exciting part of the science, the part that may genuinely add to this foundation in the years ahead, is real, and worth following carefully. The standard it has to meet is the same one medicine has always applied: does it work, in people, and does it help more than it harms?
That standard is not a barrier to progress. It is what makes progress trustworthy.
Dr. Schraga is a physician at Crescendo MD and practices personalized preventive and longevity medicine on the San Francisco Peninsula, including Portola Valley, Atherton, Los Gatos and surrounding areas.
